EKSO BIONICS (EKSO) AI Stock Analysis

• Market Cap: $10.19M
• Dividend Yield: N/A
• Average Volume (3M): 41.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.66
• Revenue Growth: -19.32%
• EPS Growth: 44.73%
• Country: US
• Employees: 61
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -1.24
• Shares Outstanding: 2,611,788
• 10 Day Avg. Volume: 34,695
• 30 Day Avg. Volume: 41,948
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.72
• Enterprise Value/Revenue: 0.50
• Enterprise Value/Gross Profit: 0.97
• Enterprise Value/Ebitda: -0.61
• 1Y Price Target: $6.00
• Price Target Upside: 40.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 52 Neutral
• Price Target: $4.50 ▲(5.14% Upside)

EKSO BIONICS' overall stock score is primarily impacted by its financial performance, which shows significant challenges with profitability and cash flow. Technical analysis provides some positive momentum, but valuation metrics are weak due to negative earnings. The earnings call further underscores financial difficulties, despite some strategic initiatives and growth in specific segments.

Positive Factors

Growth in Personal Health Segment

The significant growth in the Personal Health segment indicates strong demand and market acceptance, which could drive long-term revenue stability and expansion opportunities.

Strategic Partnerships

Strategic partnerships enhance market access and distribution capabilities, potentially leading to increased sales and market penetration over time.

AI and Innovation Initiatives

Integrating AI into products can enhance functionality and user experience, providing a competitive edge and fostering innovation-driven growth.

Negative Factors

Significant Revenue Decline

A sharp decline in revenue indicates potential issues in sales execution or market demand, which could affect financial stability if not addressed.

Decreased Gross Margin

A declining gross margin suggests rising costs or pricing pressures, which could impact profitability and necessitate cost management strategies.

Increased Net Loss

An increasing net loss highlights ongoing financial challenges, underscoring the need for improved cost control and revenue generation to achieve profitability.

EKSO BIONICS Business Overview & Revenue Model

Company Description

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.

How the Company Makes Money

EKSO BIONICS generates revenue through the sale of its exoskeleton products to hospitals, rehabilitation centers, and industrial clients. The company also earns income from leasing its devices, providing training and support services, and ongoing maintenance contracts. Key revenue streams include direct sales of exoskeleton systems, recurring revenue from service agreements, and partnerships with healthcare organizations and rehabilitation facilities that integrate EKSO's technology into their treatment programs. Additionally, EKSO may benefit from collaborations with research institutions and grants that support the development of innovative rehabilitation technologies.

EKSO BIONICS Financial Statement Overview

Summary

EKSO BIONICS faces ongoing financial challenges with negative profitability and cash flow metrics. Despite improvements in operational efficiency and cash flow management, persistent losses and reliance on external financing remain concerns. The moderate leverage and stable equity position offer some stability, but consistent revenue growth and profitability are crucial for long-term sustainability.

Income Statement

EKSO BIONICS has shown a volatile revenue trajectory with a slight revenue decline of 1.94% from 2023 to 2024. The gross profit margin improved to 53.06% in 2024 from 49.68% in 2023, indicating efficiency in controlling direct costs. However, the company continues to face challenges with profitability, as evidenced by a negative net profit margin of -63.21% in 2024, despite improving from -83.17% in 2023. The EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.

Balance Sheet

EKSO BIONICS' balance sheet reflects a stable equity position with an equity ratio of 47.68% as of 2024. The debt-to-equity ratio stands at 0.47, indicating moderate leverage, which has slightly decreased from 0.57 in 2023. However, the return on equity remains negative at -89.17% due to persistent net losses, highlighting a challenging environment for shareholder returns.

Cash Flow

The cash flow statement reveals a negative free cash flow for 2024, although it improved by 19.46% compared to 2023. The operating cash flow to net income ratio is 0.87, suggesting that operational cash generation is not sufficient to cover net losses. The company is heavily reliant on financing activities to support cash flow needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.65M	17.93M	18.28M	12.91M	11.25M	8.88M
Gross Profit	7.55M	9.51M	9.08M	6.21M	6.75M	5.07M
EBITDA	-11.96M	-9.45M	-13.20M	-14.04M	-9.09M	-15.07M
Net Income	-11.09M	-11.33M	-15.20M	-15.08M	-9.76M	-15.82M
Balance Sheet
Total Assets	23.17M	26.65M	28.92M	40.90M	49.17M	20.60M
Cash, Cash Equivalents and Short-Term Investments	5.24M	6.49M	8.64M	20.52M	40.41M	12.86M
Total Debt	5.39M	5.98M	7.17M	7.50M	2.22M	3.86M
Total Liabilities	12.24M	13.95M	16.31M	15.46M	11.95M	16.16M
Stockholders Equity	10.93M	12.71M	12.61M	25.44M	37.22M	4.43M
Cash Flow
Free Cash Flow	-9.15M	-9.88M	-12.21M	-14.88M	-11.21M	-8.76M
Operating Cash Flow	-9.12M	-9.85M	-12.05M	-14.69M	-11.16M	-8.76M
Investing Cash Flow	-79.00K	-37.00K	-157.00K	-5.17M	-59.00K	0.00
Financing Cash Flow	8.52M	7.77M	348.00K	176.00K	38.71M	10.70M

EKSO BIONICS Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EKSO, the sentiment is Positive. The current price of 4.28 is above the 20-day moving average (MA) of 3.91, above the 50-day MA of 3.67, and below the 200-day MA of 6.18, indicating a neutral trend. The MACD of 0.13 indicates Negative momentum. The RSI at 62.60 is Neutral, neither overbought nor oversold. The STOCH value of 61.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EKSO.

EKSO BIONICS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EKSO	52 Neutral	$10.19M	―	-96.44%	―	-19.32%	44.73%
HBIO	52 Neutral	20.76M	-0.37	-364.88%	―	-12.24%	-427.45%
MLSS	46 Neutral	43.28M	-6.19	-208.80%	―	7.84%	-43.00%
FEMY	44 Neutral	15.34M	-0.42	-816.54%	―	98.61%	-1.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%